Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Is Sorrento getting closer to DARPA?
"ANP Technologies®, Inc., originally spun out from the U.S. Army Research Laboratory in 2002, is an innovation-driven company which has successfully developed multiple product platforms based on proprietary/patented nanobiomaterials and the nanoscale manipulation of their spatial orientation. We have focused the application of our technologies, known as the Nano-Intelligent Detection/Delivery System (NIDS®), on the following major areas of application:

Drug Delivery
Encapsulation of poorly soluble drugs in nanoparticles using our library of polymers improves their solubility and therapeutic outcomes. We have coined the term “nanoencapsulation” to describe our polymer technology’s ability to increase the safety and efficacy of poorly-soluble and highly cytotoxic compounds in the treatment of various diseases and pathologies. In collaboration with our partners, various nanoencapsulated poorly soluble drugs for IV injection have been developed for the treatment of lung, breast, ovarian, pancreatic cancers, as well as CNS related diseases.



Rapid Detection of Biowarfare Agents
ANP has developed rapid lateral-flow immunoassays currently fielded by the US Department of Defense and Department of Homeland Security for the detection of biowarfare/biothreat agents. By employing nanomanipulation techniques, our NIDS® assay is the only handheld assay that does not suffer from the deadly false negative high-dose hook effect that has plagued all the other handheld assays on the market. Additional multiplexed detection capability along with the use of a handheld reader that completely eliminates human to human reading and environmental lighting variations has made the NIDS® rapid assays the top choice for military, state and local first responders."